licensing is based on reduced toxicity rather than efficacy. CD34-positive cell-enrichment is also used to decrease cancer cell contamination of autografts in women with breast Relapse due to either residual host disease or reinfused tumor cells remains the principal cause of treatment cancer, 6-8 and people with non-Hodgkin lymphoma. 9 This technique results in the loss of about half of CD34-positive failure after autologous stem cell transplantation. Although it is intuitively attractive to remove putative cells processed and a 2-3 log depletion of T and B cells 10 and cancer cells.
and cancer cells. 1, 6 Loss of CD34-positive cells is usually tumor cells from autologous grafts prior to transplant and more than 1000 articles have been written on the compensated for by increasing numbers of CD34-positive cells collected. Data of immune recovery after transplants subject, there are only limited data suggesting that purging autografts has any favorable effect on relapses of CD34-positive cells are not reported. This could be important since, in addition to removing T and B cells, or disease-free survival. Certain purging techniques that remove substantial numbers of T cells or destroy monocytes (CD14 + ), natural-killer cells (CD56 + ) and T helper (CD4 + ) cells are also lost; these losses may delay progenitor cells may have adverse effects such as delayed hematopoietic or T cell reconstitution. There is immune recovery. The complete remission rate of 8% reported by Schiller and coworkers is lower than most other a critical need for large, well-designed trials that specifically address the value of a particular purging reports of autotransplants in multiple myeloma using unmodified grafts; 3-5 could this be from loss of immune technique on relapses and disease-free survival after autologous stem cell transplant. cells or some other adverse effect of CD34-positive cell selection? Keywords: purging; autologous stem cell transplant; CD34 selection; multiple myeloma
There is an on-going US randomized trial evaluating CD34-positive cell-enriched autotransplants in people with newly diagnosed multiple myeloma. This study is premature, however, since less than one-half of trial entrants will In this issue of Bone Marrow Transplantation, Schiller and achieve a complete remission post-transplant. 3, 11, 12 Consecoworkers report data on engraftment, response rate and outquently, it will be difficult, if not impossible, to assess the come for 55 people with drug-sensitive multiple myeloma benefit of removing myeloma cells from the graft in the receiving high-dose therapy followed by blood cell autoone-half of people with less than complete remission who transplants of CD34-positive enriched cells (Ceprate; have residual myeloma. However, adverse effects of CD34-CellPro, Bothell, WA, USA). This study adds 18 new subpositive cell selection might be detected. Such an adverse jects and added follow-up of a previous report. 1 Engraftment outcome is not implausible; preliminary analysis of a was satisfactory in most people in the current study; howrandomized trial of conventional vs CD34-positive cellever, eight subjects (15%) receiving Ͻ2 × 10 6 CD34 + enriched autotransplants in women with metastatic breast cells/kg had significantly delayed platelet recovery and cancer showed worse event-free survival in the CD34-increased platelet transfusions compared to the 47 subjects positive cell-enriched cohort. 8 receiving Ͼ2 × 10 6 CD34-positive cells/kg. Response rate Blood cell autotransplants are increasingly used to treat was 72%, but only 8% of patients had a complete response.
cancer. Relapse after autotransplants usually result from Three-year progression-free survival of 29% is similar to residual cancer in the subject. Cancer cells infused with the reports of unmodified blood cell autotransplants. [2] [3] [4] [5] autograft may also contribute to relapse. Since it is easier CD34-positive cell-enrichment was used to remove possto deplete the graft than the subject of cancer cells, intense ible contaminating myeloma cells from the graft; these cells research activity is focused on new and better purging techare presumed to contribute to relapse in people with mulniques. More than 1000 articles written about purging have tiple myeloma. CD34-positive cell-enrichment using the been published since 20 who reported that of stem and committed progenitor cells resulting in delayed bone marrow recovery, especially platelet recovery. 13, 14 autotransplant recipients with low-grade non-Hodgkin lymphoma whose bone marrow graft was treated with anti-B Other less widely evaluated techniques include: CD34-positive cell enrichment using magnetic beads (Baxter Laboracell monoclonal antibodies and complement and who had a negative PCR for bcl-2 rearrangement had a 20% probtories, Santa Ana, CA, USA), high-speed cell sorting (Systemix, Palo Alto, CA, USA), physical separation ability of relapse compared to Ͼ85% relapses in people with a positive PCR test after in vitro treatment. These data (density gradient), in vitro cultivation or cell expansion and incubation with anti-sense cDNA.
might mean that infusing of lymphoma cells causes relapses. However, it is also possible that people with a Despite intense research, there are few convincing data that infused cancer cells in the grafts cause relapses after negative PCR have less lymphoma which may be more sensitive to drugs and radiation than people with more lymautotransplants or that selection or purging techniques improve transplant outcome. These techniques are laborphoma. Also, unclear is whether outcome for all people receiving purged grafts was better than would have been intensive, potentially delay bone marrow recovery and increase cost. Consequently, it is important to determine if expected following infusion of unpurged grafts. 25 In breast cancer, bone marrow involvement by cancer cells purging increases survival in randomized trials rather than using removal of cancer cells from the autograft as a correlates with outcome in all stages regardless of treatment. 26, 27 Therefore, data that patients receiving autografts surrogate.
Data from animal models clearly show that infusing cancontaining cancer cells have a worse outcome is not surprising. 26, 27 This makes evaluating the contribution of cancer cer cells can cause cancer. Important variables include type of cancer, genetics and immune state of the recipient. Anicells in the autograft difficult and points out the fallacy of using in vitro assays of efficacy of cancer cell removal from mal studies by Hagenbeek and coworkers, 17 attempting to mimic autotransplants in acute myelogenous leukemia the graft as a surrogate for clinical effectiveness. In AML, purging with 4-hydroperoxycyclosphosphamide (AML) in humans, concluded that Ͻ10% of relapses were from the graft and the remainder from residual leukemia or mafosphamide was evaluated in phase-2 trials; no randomized trials are reported. 13, 14 Two retrospective analyses cells in the recipient. These studies predicted that purging would be relatively ineffective in improving autotransplant suggest 10-15% fewer relapses after purged vs unpurged autotransplants. 14, 28 Purging in AML does not invariably outcomes in AML.
Gene marking studies in humans indicate that cancer translate to better survival because of increased treatmentrelated mortality. 13 A recent application to the FDA for cells from the graft can contribute to relapse after autotransplants for AML, neuroblastoma and chronic myelogenous licensing of 4-hydroperoxycyclosphosphamide was rejected. leukemia. 18, 19 Patients with a high likelihood of cancer in the graft, however, also have a high likelihood of residual cancer in them even after grafts from normal donors.
Randomized trials
There are few randomized trials of purging. There are several reasons for this but the major one is the large number Other diseases of subjects needed to determine efficacy. As long as most relapses result from residual cancer in the subject, definitive Several purging techniques are used in people with lymphoma. 9, 15, 20, 21 There are no randomized trials of purging of purging studies will be difficult, if not impossible, to perform. This problem is confounded by the fact that cancer autografts. The European Bone Marrow Transplant Group analyzed 448 patients with non-Hodgkin lymphoma receivcells in the graft do not invariably cause relapses.
22
ing purged or unpurged bone marrow autotransplants. 21 Purging techniques included monoclonal antibodies with complement or magnetic beads and drugs. These analyses Cost showed no decrease in relapse or increase in EFS for patients receiving purged grafts. These data suggest that Costs for purging using the Ceprate device is about $7000 and double if more than two aphereses are required to achieither infusing lymphoma cells had no impact or that purging techniques were ineffective (or both).
eve the desired dose of CD34-positive cells. CD34-positive cell-enrichment with the Ceprate device recovers approxiThere are few if any sensitive techniques to detect residual cancer in most people with non-Hodgkin lymmately one-half of CD34-positive cells. [6] [7] [8] [9] In not extensively pretreated subjects this may not be a problem since phoma. Most purging studies evaluated efficacy indirectly by efficiency of removing T or B cells. 15 Polymerase chain blood CD34-positive cell yields are usually high. Unfortunately, people with the highest likelihood of cancer conreaction (PCR) analysis is used to evaluate efficacy of purging in people with specific cytogenetic abnormalities like tamination of their autograft may also be those with low CD34-positive cell yields in which more than two apherthe t(14;18) translocation in which bcl-2 is rearranged. 20 Detection of this rearrangement in bone marrow or blood eses may be needed. Post-transplant platelet recovery is directly correlated with is not, however, invariably associated with relapse.
22,23
Additionally, detecting bcl-2 rearrangement in bone mar-CD34-positive cell dose. 29-31 A dose of у5 × 10 6 CD34-positive cells/kg is needed to assure recovery of platelets to row is more predictive of transplant outcome than detecting it in blood. 
